良性前列腺增生和癌的关系

良性前列腺增生和癌的关系南京大学医学院附属鼓楼医院泌尿外科（２１０００８）周志耀前列腺增生症（ＢＰＨ）与前列腺癌（ＰＣ）共存在一个腺体，是长期有争议的问题。早在１９２２年Ｇｅｒａｐｈｙ就报道ＰＣ中有７５％伴有ＢＰＨ。而在ＢＰＨ中，当今国内外均发现有５...     

老年人良性前列腺增生与心血管疾病的关系

目的 了解老年良性前列腺增生(BPH)患者临床特点及用药情况,探讨BPH与心血管疾病的关系. 方法 搜集本院老年病科100例BPH患者临床资料,采用国际前列腺症状评分表(IPSS)、生活质量量表(QOL)对患者进行评价,所有患者均详细询问心血管病史,并检测前列腺特异性抗原(PSA)水平,采用腹部超声测量前列腺体积(PV). 结果 老年BPH患者PV和PSA随年龄增长而升高;疾病严重程度以中度(IPSS 8～19分)多见;BPH患者高血压、冠心病和糖尿病患病率高,冠心病者PV显著高于非冠心病者(P＜0.05);我院BPH患者服用5-α还原酶抑制剂和α-受体阻滞剂者多见,治疗依从性好. 结论 老年BPH患者严重程度与年龄、冠心病发病相关;药物干预治疗以5-α还原酶抑制剂使用率最高.     

老年人良性前列腺增生与心血管疾病的关系

Objective To realize the clinical characteristics and treatment strategies in elderly patients with benign prostatic hyperplasia (BPH), and investigate the correlation between severity of BPH and cardiovascular diseases. Methods One hundred consecutively referred patients with BPH were enrolled in this study, and the international prostate symptom score (IPSS) and quality of life (QOL) scores were recorded. All patients were queried in detail about history of cardiovascular disease, and underwent detection of prostate specific antigen (PSA) levels, prostate volume (PV)measurement by abdominal ultrasound. Results PV and serum PSA level increased with age.Forty-eight percent of patients had a moderately enlarged prostate (IPSS 8-19). Patients with BPH had higher incidence of hypertension, diabetes, as well as coronary artery disease (P＜0.05). The most common medical treatments were 5α-reductase inhibitors and a-receptor blockers in our hospital and most patients had good compliance. Conclusions The severity of BPH is correlated with age and morbidity of coronary artery disease. For the drug intervention therapy, 5a-reductase inhibitors have the highest utilization rate.     

良性前列腺增生与血脂异常

目的 探讨体检人群中老年人良性前列腺增生(BPH)与血脂异常的相关性. 方法 选择在我院体检的中老年男性共401例,通过现场询问病史,国际前列腺症状评分(IPSS),直肠指诊,经直肠B超分为两组:(1)BPH组192例;(2)非BPH组209例.比较两组血脂水平及危险分层差异. 结果 两组血脂水平[三酰甘油(TG):t=0.388,P=0.698;总胆固醇(TC):t=0.449,P=0.654;低密度脂蛋白胆固醇(LDL-C):t=0.151,P=0.880;高密度脂蛋白胆固醇(HDL-C):t=0.628,P=0.531)]、心血管病综合危险的评价分层(X2=4.094,P=0.251)差异均无统计学意义;IPSS评分与血脂异常亦无明显相关性(TG:X2=5.855,P=0.054;TC:X2=3.813,P=0.149;LDL-C:X2=1.704,P=0.427;HDL-C:X2=3.289,P=0.193). 结论 BPH并存血脂异常临床多见,但在BPH下尿路症状以轻中度为主的体检人群中.二者之间的相关性不如以需手术治疗的中重度BPH患者为纳入人群的类似研究关系明确,其机理尚有待进一步研究证明.     

老年人前列腺外腺低回声结节与良性前列腺增生的关系

目的经直肠超声（TRUS）引导行前列腺穿刺活检，探讨老年人前列腺外腺低回声结节与良性前列腺增生（BPH）的关系。方法对420例疑患前列腺癌患者行TRus引导下行前列腺穿刺活检，其血清前列腺特异性抗原（PSA）为0．7～32．9μg／L，平均9．4μg／L。结果420例穿刺病理检查，253例（60．2％）为前列腺良性病变，167例（39．8％）为前列腺癌；经TRUS检查，194例（46．2％）发现前列腺外腺存在低回声结节的患者中，20例（10．3％）经病理诊断为BPH，其中声像图显示17例外腺结节呈卵圆形，边界清楚，表面光滑。结论TRUS显示的前列腺外腺低回声结节有良性增生的可能性，但须与前列腺癌鉴别。     

老年人代谢综合征与良性前列腺增生的关系

目的 回顾性分析老年代谢综合征(MS)与良性前列腺增生(BPH)的关系.方法 老年男性859名,其中单纯MS患者8例,单纯BPH患者619例,两种疾病并存者192例,未患病者40例.检测空腹血糖(FBG)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C),并计算体质指数(BMI)、前列腺体积及前列腺年增长率(PG),分析代谢性危险因素与BPH的相关性.结果 BPH患者MS组与非MS组相比收缩压、舒张压、体质量、BMI、TG及FBG偏高(t=6.15、5.99、13.12、15.56、10.63、9.94,均P＜0.01),HDL-C浓度偏低(t=-7.57,P＜0.01);随着MS组分个数的增加,前列腺体积增加(F=2.98,P=0.031);随着年龄、体质量、BMI、收缩压、PG的增加,前列腺体积增大(t值分别为-6.39、-2.39、-2.36、-2.13、-25.85,均P＜0.05);前列腺体积与年龄、收缩压、体质量、BMI、血压升高呈正相关(r值分别为0.229、0.079、0.090、0.089、0.088,均P＜0.05);非条件Logistic回归分析校正混杂因素后,年龄、体质量和收缩压＞130 mm Hg(1 m Hg=0.133 kPa)为前列腺增生的独立相关因素(OR值分别为1.07、1.03、1.34,均P＜0.05).结论 老年患者BPH与MS有关,MS可能参与老年人BPH的发生发展过程,但其机制尚有待进一步研究.

Abstract：

Objective To retrospectively analyze the relationship between benign prostatic hyperplasia (BPH) and metabolic syndrome (MS) in senior patients. Methods The 859 male senior patients including 619 cases with BPH and 8 cases with MS were enrolled in this study, and there were 192 cases with both diseases and 40 controls. The levels of fasting blood glucose (FBG), total cholesterol (TC), triacylglycerol (TG), low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) were measured. The body mass index (BMI), prostate volume and annual prostate growth rate were determined or calculated. The correlations of BPH with other metabolic risk factors were analyzed. Results The levels of systolic blood pressure (SBP), diastolic blood pressure (DBP), body weight, BMI, TG and FPG were higher (t=6.15, 5.99, 13.12, 15.56, 10.63 and 9.94, all P＜0.01), while serum HDL-C level was lower (t=-7.57,P＜0.01) in BPH patients with MS than without MS. As the number of components of MS was increased, the prostate volume was increased (F=2.98, P=0.031). As the age, body weight, BMI, SBP and PG were increased, the prostate volume was increased (t=-6.39,-2.39,-2.36,-2.13,-25.85,all P＜0.05). Spearman analysis showed that prostate volume was positively correlated with age, SBP, body weight, BMI and hypertension (r=0.229, 0.079, 0.090, 0.089 and 0.088, all P＜0.05). And age, body weight and SBP were the independent risk factors for BPH (OR=1.07, 1.03 and 1.34, all P＜0.05). Conclusions The present study demonstrates a relationship between BPH and MS in senior patients. Future studies are needed to confirm our results and to explain underlying mechanisms.     

良性前列腺增生与肥胖相关性研究

目的 探讨良性前列腺增生(BPH)与肥胖或中心性肥胖的关系.方法 选择老年男性患者109例,分为BPH组(59例)和非BPH组(50例),检测血清前列腺特异性抗原(PSA)及性激素、血脂等相关生化指标;测量身高、体质量、腰围等物理指标;经腹超声测量前列腺体积,并随访至少3次.结果 肥胖组BPH患病率(73.33%)及超体质量组BPH患病率(64.28%)均较正常组(26.67%)增高(x2分别为13.991,6.836,均P＜0.002),中心性肥胖组BPH患病率(71.19%)较非中心性肥胖组(36.00%)明显增高(x2=12.156,P＜0.001);BPH组腰围身高指数、腰围、体质量、体质指数、臀围[0.56±0.05、(93.6±8.8)cm、(72.6±9.7)kg、(25.7±3.4)kg/m2和(100.2±6.6)cm]明显高于非前列腺增生组[0.52±0.06、(87.0±10.1)cm、(64.5±9.3)kg、(23.1±2.9)kg/m2和(95.6±8.1)cm](t分别=-3.30,-3.65,-4.38,-4.17,-3.18,均P＜0.01);肥胖组前列腺总体积高于正常组[(40.8±23.5)ml与(20.1±6.1)ml,t=-2.82,P＜0.01),中心性肥胖组明显高于非中心性肥胖组[(42.8±25.6)ml与(26.9±11.2)ml],(t=-3.93,P＜0.001);中心性肥胖组雌二醇/总睾酮(E2/TT)比值、胰岛素抵抗指数(HOMA-IR)(9.06±4.36、2.81±2.80)高于非中心性肥胖组(7.38±3.11、1.55±0.76)(t分别=-2.02,-4.24,均P＜0.05),血清TT、性激素结合蛋白(SHBG)则低于非中心性肥胖组[(4.54±1.54)nmol/L对(5.20±1.54)nmol/L,(45.8±17.24)nmol/L对(59.6±26.09)nmol/L,均t分别=2.16,2.79,P＜0.05];Logistic逐步回归分析表明,腰围是影响前列腺体积的主要因素(x2=19.52,P=0.000);前列腺总体积的年增长率在肥胖组同样高于正常组[(7.14±8.09)ml与(1.49±5.14)ml,t=-2.19,P＜0.05],在中心性肥胖组明显高于非中心性肥胖组[(7.96±13.81)ml与(1.35±5.36)m1,t=-3.28,P＜0.01];中心性肥胖组的前列腺特异性抗原密度(PSAD)低于非中心性肥胖组(0.048±0.036对0.090±0.093,t=2.02,P＜0.05);肥胖组的PSAD低于正常组(0.052±0.039与0.091±0.080,t=3.13,P＜0.01).结论 BPH的发生与肥胖,尤其是中心性肥胖密切相关,其机制可能与肥胖患者体内性激素失衡、生长激素-胰岛素样生长因子轴的紊乱有关.

Abstract：

Objective To explore the relationship between benign prostatic hyperplasia (BPH)and obesity. Methods The 109 elder men were divided into two groups: BPH group (n=59) and non-BPH group (n= 50). The blood samples were collected for the detections of prostate specific antigen (PSA), triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), fasting blood glucose (FBG), insulin,androgen, estrogen, sex hormone binding globulin (SHBG) and dehydroepiandrosterone(DHEA).The anthropometric indexes including height, body weigh, waist circumference (WC), hip circumference (HC), systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), waist-to-height ratio (WHtR) and waist-to-hip ratio (WHR) were measured and calculated. The total prostate volume (TPV) were measured by transabdominal ultrasonography three times at least. Results The morbidity rate of BPH was significantly higher in obesity group and over weight group than in health control group (73.33% and 64.28% vs. 26. 67%, x2 = 13. 991 and 6. 836, both P＜0. 002). So was in central obesity group versus in health control group (71.19% vs.36.00%, x2 =12. 156, P＜0. 001). The waist-height index, waist circumference, body weight, BMI and hip circumference were significantly higher in BPH group than in non-BPH group [(0. 56±0. 05)vs. (0.52±0.06), (93. 6±8.8) cm vs. (87.0± 10. 1) cm; (72.6±9.7) kg vs. (64.5±9.3) kg;(25.7±3.4) kg/m2 vs. (23.1±2.9) kg/m2; (100.2±6.6) cm vs. (95.6±8. 1) cm; t=-3.3, -3. 65, -4.38, -4. 17 and -3.18, respectively, all P＜0.01]. The TPV was higher in obesity groupthan in normal group [ (40.8± 23.5 ) ml vs. (20. 1 ± 6.1 ) ml, t = - 2.82, P＜ 0. 002] and obviously higher in central obesity group than in non-central obesity group [(42.8±25.6)ml vs. (26. 9±11.2)ml, t= -3. 93, P＜0. 001]. The ratio of E2/TT and HOMA-IR were higher in central obesity group [(9. 06±4.36) and (2.81 ±2. 80)] than in non-central obesity group [(7. 38±3. 11) and (1. 55±0.76), t= -2.02 and -4.24, both P＜0. 05]. Inversely, the TT and SHBG were lower in central obesity group than in non-central obesity group [(4.54 ± 1.54) nmol/L vs. (5.20 ± 1.54) nmol/L,(45.8± 17.24) nmol/L vs. (59.6 ± 26.09) nmol/L, t = 2.16 and 2.79, both P＜ 0. 05]. Logistic regression analysis showed that waist circumference was a major factor affecting TPV (x2= 19.52, P=0. 000). The annual growth rate of TPV was significantly higher in obesity group and central obesity group than in health control group [(7. 14±8. 09)ml vs. (1. 49±5.14)ml, (7. 96±13.81)mlvs. (1. 35±5.36)ml, t=-2.19 and -3.28, both P＜0. 05]; The PSAD was significantly lower in central obesity group than in health control group [(0. 048±0. 036) vs. (0. 090±0. 093), t=2.02, P＜0. 05], and lower in obesity group than in health control group [(0. 052 ±0. 039) vs. (0. 091 ±0. 080), t= 3. 13, P＜0. 01]. Conclusions The occurrence of BPH is closely related to obesity,especially central obesity. Its mechanism may be related to sex hormone imbalance and the GH/IGF-1 axis disorders in obese patients.     

良性前列腺增生患者前列腺增生组织中survivin和p38MAPK的表达

良性前列腺增生(BPH)发生与细胞凋亡减少密切相关.存活素(survivin)是凋亡抑制家族的成员,是迄今为止发现的最强凋亡抑制因子.survivin可通过多种途径抑制细胞凋亡,是凋亡调控过程中的关键因子[1].     

老年良性前列腺增生与慢性阻塞性肺疾病的关系

目的 观察老年良性前列腺增生(BPH)合并慢性阻塞性肺疾病(COPD)患者的临床特点及用药情况,探讨BPH与COPD的关系.方法 回顾性分析100例BPH患者临床资料,采用国际前列腺症状评分表(IPSS)、生活质量量表(QOL)对患者进行评价,所有患者均详细询问病史,并检测前列腺特异性抗原(PSA)水平,超声测量前列腺体积(PV).结果 老年BPH患者PV和PSA随年龄增长而增高;疾病严重程度以中度(IPSS 8～19分)多见;COPD者合并BPH较其他呼吸疾病合并BPH者多见,COPD组PV显著高于非COPD组合并BPH者(P＜0.05);我院BPH患者服用5-α还原酶抑制剂和α受体阻滞剂者多见,治疗依从性好.结论 老年BPH患者严重程度与年龄、COPD相关;药物治疗以5-α还原酶抑制剂使用率最高.     

糖尿病与良性前列腺增生的相关性研究

目的：探讨糖尿病与良性前列腺增生（BPH）发生和进展的相关性。方法：对临床明确诊断BPH 190例患者的临床资料进行分组对比分析。结果：190例患者中,单纯BPH组100例,BPH合并糖尿病者90例（47.4%）。BPH合并糖尿病组患者的国际前列腺症状评分（IPSS）明显大于单纯BPH组[（23.72±6.08）分比（21.49±7.83）分,P〈0.05],最大尿流率（Qmax）明显小于单纯BPH组[（8.0±4.6）ml/s比（9.9±5.3）ml/s,P〈0.05]。在BPH患者中,空腹血糖异常组患者的IPSS[（24.07±4.73）分比（22.34±5.12）分]、前列腺体积[（75.41±58.36）ml比（72.04±40.49）ml]明显大于空腹血糖正常组（P〈0.05）;而餐后正常血糖组与餐后异常血糖组各指标比较均无显著性差异（P均〉0.05）。与单纯BPH组相比,BPH合并糖尿病组的不同糖尿病病程患者的BPH各指标无显著性差异（P均〉0.05）。结论：良性前列腺增生同时合并糖尿病多见;糖尿病尤其异常空腹血糖水平可促进良性前列腺增生的发生以及进展。     

胰岛素抵抗与良性前列腺增生的相关性研究

目的 探讨胰岛素抵抗与良性前列腺增生间(BPH)的关系. 方法 选取在我院行健康体检老年男性200例,根据前列腺体积(PV)分为对照组(PV≤20 ml)100例,BPHl组(PV 21～49ml)50例,BPH2组(PV≥50 ml)50例.采用己糖激酶法测定空腹血糖(FPG),放免法测定空腹胰岛素(FSI)水平,运用HOMA模型计算胰岛素抵抗指数(IRI);测量身高和体质量,并计算体质指数.结果 BPH1组IRI(1.10±0.18)和体质指数(22.0±3.0)与对照组(1.18±0.21和21.8±2.7)比较,差异无统计学意义(均P＞0.05);BPH2组IRI(1.31±0.19)和体质指数(24.8±3.29)较对照组明显增高(P=0.01,0.03).高血糖所占比例BPH组(25%)高于对照组(5%)(P=0.00),其中BPH2组高血糖所占比例更高(36%)(P=0.01);BPH2组高血糖组IRI(1.47±0.21)较对照组(1.34±0.18)明显增高(t=3.92,P=0.00),但体质指数(25.8±4.3)kg/m2与对照组(24.3±2.7)kg/m2比较,差异无统计学意义(t=0.06,P=0.95). 结论 高血糖和胰岛素抵抗与重度前列腺增生存在相关性,且胰岛素抵抗的存在不依赖于体质指数的改变.     

代谢综合征与良性前列腺增生的相关性研究

目的 探讨代谢综合征(MS)与良性前列腺增生症(BPH)发生发展的相关性.方法 纳入2008年9月至2010年1月于北京大学人民医院老年科住院的男性MS患者101例;同时纳入同期的非MS男性患者117例.测量血压、身高、体质量、计算体质指数(BMI),并检测空腹血糖( FBG)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)和前列腺特异性抗原(PSA),超声测量及计算前列腺体积(PV).结果 MS组患者PV为(39.7±21.1)ml明显大于非MS患者的(30.7±9.3)ml(P＜0.05).PSA两组比较差异无统计学意义(P＞0.05).PV与BMI(r= 0.37,P=0.001)、高血压病程(r=0.27,P=0.019)、PSA(r=0.51,P=0.001)、FBG(r=0.24,P=0.013)、收缩压(r=0.20,P=0.047)呈正相关(P＜0.05),与HDL-C呈负相关(r=-0.24,P=0.013).结论 BMI,高血压病程,PSA,FBG,收缩压和低HDL-C水平可能是BPH发生发展的危险因素.     

经尿道前列腺等离子电切治疗80岁及以上前列腺增生患者临床观察

目的 探讨经尿道前列腺等离子双极电切术(PKRP)治疗80岁及以上前列腺增生 (BPH)患者的有效性及安全性.方法 回顾分析PKRP治疗的180例80岁及以上高危BPH患者的临床资料.结果 180例手术顺利,手术操作时间平均(45.5±23.3)min.平均切除前列腺(60.3±23.3)g,无输血病例,术中无闭孔神经反射电切综合征出现.术后国际前列腺症状评分由(29.5±5.3)分降至(10.2±2.8)分;最大尿流率由(6.2±1.8)ml/s上升至(24.5±3.1)ml/s;生活质量评分由术前的(7.2±1.1)分下降至(1.0±0.5)分;残余尿由(130.5±45.5)ml降至(13.5±7.1)ml(均P＜0.05).结论 PKRP具有安全性高、并发症少、前列腺切尽率高、疗效确切等优点,适宜高龄BPH患者的手术治疗.

Abstract：

Objective To study the efficacy and safety of transurethral plasmakinetic resection of prostate (PKRP) in treatment of benign prostate hyperplasia in elderly patients aged 80 years and over. Methods Retrospective clinical analysis of 180 case of high risk of benign prostate hyperplasia treated by PKRP in patients aged 80 years and over. Results All the 180 patients underwent the operation successfully. The average time for operation was (45.5±23.3) min and the resected prostate was in an average of (60.3±23.3) g. Neither of blood transfusion during the operation nor aductor reflex and transurethral resection syndrome occurred. International prostate symptom score,residual urine and quality of life decreased from (29.5±5.3) to (10.2±2.8),from (130.5±45.5) ml to (13.5±7.1)ml and from (7.2±1.1) to (1.0±0.5) respectively. The maximum flow rate elevated from (6.2±1.8) ml/s to (24.5±3.1) ml/s. The differences in the above indicators were statistically significant between pre- and post- operation (P＜0.05). Conclusions Transurethral plasmakinetic prostatectomy is a reliable and effective surgical method, especially for the aged patients with benign prostate hyperplasia.     

经尿道前列腺等离子剜除术与电切术治疗前列腺增生的疗效比较

目的 比较经尿道前列腺等离子双极电切剜除术(TUPKEP)与经尿道前列腺电切术(TURP)治疗良性前列腺增生(BPH)的临床疗效及安全性.方法 将142例BPH患者分为两组,TUPKEP组72例,年龄52～90岁,平均(70.5±7.6)岁,前列腺质量27～126 g,平均(75.6±10.3)g;TURP组70例,年龄51～87岁,平均(70.2±6.8)岁,前列腺质量25～118 g,平均(73.8±9.9)g.两组患者术前年龄、前列腺质量、前列腺症状评分(IPSS)、剩余尿量、最大尿流率、生活质量评分(QOL)比较,差异均无统计学意义(t值分别为0.2873、1.0612、1.0832、0.9522、0.0000、1.0774;P值分别为0.7743、0.2904、0.2806、0.3426、1.0000、0.2832).比较两组手术时间、术中出血量、术后尿管留置时间、住院天数、术后并发症发生率及疗效.结果 TUPKEP组72例均获成功(100.0%),TURP组成功69例(98.6%).TUPKEP、TURP组平均手术时间分别为(46.2±6.4)min、(58.4±9.6)min,组间比较差异有统计学意义(t=8.9404,P-0.0000);两组术中出血量分别为(105.9±12.2)ml、(148.6±14.3)ml,组间比较差异有统计学意义(t=19.1608,P=0.0000);两组术后平均留置尿管时间分别为(3.5±1.0)d、(5.0±1.0)d(t=8.9364,P=0.0000);两组术后平均住院时间分别为(5.1±1.9)d、(7.0±0.6)d(t=4.9819,P=0.0000).TUPKEP组术后发生暂时性尿失禁1例,继发前列腺出血2例,尿道外口狭窄1例,并发症发生率5.56%,TURP组发生经尿道前列腺电切综合征2例,尿外渗1例,术后暂时性尿失禁2例,继发前列腺出血3例,尿道外口狭窄2例,并发症发生率14.29%.术后随访3个月,两组最大尿流率较术前明显增加,IPSS、剩余尿量、QOL均较术前明显下降,组间比较差异均无统计学意义(t值分别为1.1131、0.2543、1.2959、0.7252;P值分别为0.2676,0.7996、0.1971、0.4696).结论 TUPKEP与TURP治疗BPH的疗效相近,但TUPKEP平均手术时间短、术中出血量少、围手术期及术后并发症发生率低,手术安全性更高.     

老年人良性前列腺增生症与胰岛素抵抗

目的 观察胰岛素抵抗和空腹胰岛素(FINS)水平与老年良性前列腺增生(BPH)的关系. 方法 以2008年2月在湘雅二医院老年病科门诊就诊的BPH患者68例为观察对象,分析FINS、血清前列腺特异性抗原(PSA)、糖化血红蛋白、空腹血糖、餐后2 h血糖,计算胰岛素抵抗指数(HOMA-IR).测量血压、体质量、身高、腹围,计算体质指数.测定前列腺体积,评估下尿路症状(LUTS),并询问LUTS出现的时间. 结果 (1)按照HOMA-IR＞2.8为胰岛素抵抗,将患者分为敏感组48例和抗组20例,结果显示抵抗组患者的前列腺体积高于敏感组,分别为(61.1±32.9)ml和(40.4±16.5)ml,差异有统计学意义(P＜0.05);两组PSA分别为(3.3±2.3)μg/L与(2.9±1.3)μg/L,差异无统计学意义(P＞0.05);LUTS出现时间(13.4±6.6)年和(8.7±6.0)年,差异无统计学意义(P＞0.05);国际前列腺症状评分(IPSS)分别为(16.4±6.7)分和(13.3±7.1)分,差异无统计学意义(P＞0.05).(2)以前列腺症状药物治疗(MTOPS)研究的进展性评价指标为标准,将患者分为低进展组与高进展组,分别为30例和38例,两组FINS、HOMA-IR比较,差异有统计学意义(均P＜0.01).(3)前列腺体积与HOMA-IR、FINS呈正相关(r值分别为0.431和0.492,均P＜0.01).结论老年BPH患者存在胰岛素抵抗,胰岛素抵抗程度、高FINS水平与前列腺体积的增大及疾病进展有关.